MIF and neuroblastoma: Degradation of MIF by PROTAC treatment enhanced the efficacy of multiple neuroblastoma-targeting CAR T-cells, which provides a novel therapeutic strategy to enhance CAR-T cell efficacy in patients with neuroblastoma.